Confronto
LL-37 vs. Semax
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
597562-32-8
80714-61-0
Peso molecolare
4493.33 g/mol
813.92 g/mol
Emivita
nessun dato
0.3 h
Sequenza
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESMet-Glu-His-Phe-Pro-Gly-ProMeccanismo d'azione
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Semax
Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.
Base di evidenze
Evidenza più alta
Studio sull'uomo
Studio sull'uomo
Studi
4
4
di cui sull'uomo
1
2
Effetti registrati
4
3
Contraddizioni aperte
1
1
Eventi avversi documentati
0
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between LL-37 and Semax?
- LL-37 is classified as "Ricerca (altro)", while Semax is classified as "Ricerca (altro)". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Semax: Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic stroke, cognitive function and ADHD in children. Western phase-3 trials absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Semax?
- The highest available evidence level is "Studio sull'uomo" for LL-37 and "Studio sull'uomo" for Semax. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Semax in Germany and the United States?
- Germania: LL-37 — Solo ricerca, Semax — Non approvato. Stati Uniti: LL-37 — Solo ricerca, Semax — Non approvato. These are factual summaries with source and review date on the individual pages.